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Colorectal cancer is the fourth most common cancer in men and the third most common cancer in women worldwide. In China and other economically transitioning countries, colon cancer incidence rates have been rising rapidly, most likely owing to changes in lifestyle and nutritional habits (1) . Laboratory investigations of differences in gene expression between normal cells and their corresponding carcinoma cells are crucial to understanding how oncogenes and tumor suppressor genes alter complex cellular functions and thus drive tumor progression (2) . In colon cancer, a large number of disease biomarkers have been associated with clinical outcomes, including adenomatous polyposis coli (APC), beta-catenin, DNA mismatch repair genes, growth factors and their receptors, cell adhesion molecules, and more recently microRNAs and colon epithelial stem cell markers (3) (4) (5) (6) (7) (8) (9) . Despite this rapidly accumulating knowledge, there remains a need for biomarkers of disease progression that can be utilized in a preventive strategy to stratify patients into appropriate screening, surveillance, treatment, and prevention programs.
At present, cDNA microarrays and serial analysis of gene expression (SAGE) are the most widely used techniques for determining gene expression levels and ratios in different disease states and in cells under different physiologic conditions (10) . cDNA microarrays are used to measure the relative gene expression levels of thousands of known transcripts in different cell and tissue samples (11) (12) (13) (14) . SAGE is based on the high-throughput sequencing of concatemers of short sequence tags that originate from a known position within a transcript and therefore theoretically contain sufficient information for identification of a unique transcript. SAGE data and techniques have been utilized by a number of investigators to identify genes with differential regulation and potential contributions to colon cancer progression (15) (16) (17) (18) . However, annotation of the short, 10-bp sequence tags may identify more than one transcript (19, 20) . This lack of specificity can be overcome by using LongSAGE libraries that contain longer, 17-bp tags, thus generating more reliable mapping to Unigene clusters or the complete genome sequence (21) (22) (23) .
Cellular heterogeneity within patient samples very often presents a challenge to accurate tissue-or tumor-specific gene expression profiling. Gene expression measurements can become skewed owing to tissue heterogeneity, which in turn significantly confounds attempts at statistical analyses. This challenge can be overcome via the use of laser capture microdissection (LCM) to obtain purified cell populations from heterogeneous tissue, resulting in the derivation of precise information on the gene expression profiles of defined cell types (2, 24) . Tissue microarrays (TMAs) can then be used to confirm gene expression in the clinical context.
In the present study, we first present a LCM-LongSAGE protocol for investigating global gene expression profiling of parenchymal cells in colon carcinoma. This protocol allowed for the rapid, quantitative measurement of genome-wide gene expression in specific cell populations. Differential regulation of a subset of genes was validated by quantitative real-time polymerase chain reaction (qPCR), immunohistochemistry, and clinical correlations with patient characteristics, tumor histopathology, and patient outcomes. epithelium by LCM-microarray was described previously (25) ; this was used for the generation of LongSAGE libraries. aRNA was adjusted to a final volume of 10 μL with diethylpyrocarbonate-treated H 2 O. A total of 2 μL of SAGE-random primer (5'-NNN NNN CAT G-3'; Eurofins MWG Operon, Ebersberg, Germany) and 1 μL dNTP mix (10 mM; Promega, Madison, WI, USA) were added to the aRNA, followed by 65°C incubation for 5 min and then frozen on dry ice. A total of 4 μL first strand buffer, 1 μL 0.1 M dithiothreitol, 1 were reported for a given sample, the samples were re-evaluated, and if they were still different, the investigators discussed until a unanimous agreement was reached.
Materials and Methods

Construction
Statistical analysis. Continuous variables are presented as the mean ± standard deviation (SD). Categorical variables are expressed as the number (n) and percentage and were compared with the Fisher exact test (27) . FERMT1 and AHCY staining for the 31 matched uninvolved and carcinoma tissues were compared with the signed-rank test (28) .
Overall survival (OS) and disease-free survival (DFS) curves were calculated with the Kaplan-Meier method with log-rank test (29) . To investigate independent risk factors for death and lymph node metastasis, Cox proportional hazard models were used (30) 
Results
LongSAGE data libraries.
Pure cell populations were collected from 203 paired colon carcinoma and uninvolved mucosa specimens by LCM and were used to create a LongSAGE library. A total of 100,666 tags were generated including 45,560 unique tags (Supplemental Table 2 ). The duplication ditag proportions were 6.47 in the uninvolved colon Likewise, differential regulation of eight of the downregulated genes has been previously reported in colon cancer.
qPCR for validation of altered gene expression. qPCR was performed to validate the expression of six differentially expressed genes, four with significantly upregulated expression, and two with significantly downregulated expression. Our rationale for focusing on these genes was based on fold difference in expression, the potential function of these genes in tumor development, and the fact that there have been few or no detailed studies on these genes. Upregulation of FREMT1, AHCY, SCRN1, and SAC3D1 expression and downregulation of immunoglobulin J (IgJ) and MAL-like protein (MALL) expression in colon carcinomas were confirmed by qPCR (Supplemental Fig. 3 ).
Immunohistochemical staining of matched cancer and uninvolved colon tissues for
AHCY and FERMT1 protein expression. Among FERMT1, AHCY, secernin-1 (SCRN1), and SAC3 domain-containing protein 1 (SAC3D1), there were no commercially available antibodies for SAC3D1, and antibody for SCRN1 resulted in ambiguous immunohistochemical staining. Antibodies for FERMT1 and AHCY were found to be useful for titration and staining, but preliminary results indicated that AHCY protein expression was not a significant prognostic factor for tumor outcome. Therefore, we focused on FERMT1. Immunohistochemical detection of FERMT1 protein expression was also performed on a TMA comprised of multiple types of alimentary tumors (Fig. 1C-N 
staining was detected in all of the uninvolved gastric tissue and two gastric carcinoma specimens, whereas three gastric carcinoma tissues showed moderate FERMT1 protein staining. In contrast, FERMT1 protein was upregulated in all of the colon and rectal carcinomas on the TMA. Thus, upregulated FERMT1 protein expression appeared to support the tissue-specific nature of FERMT1 expression.
Clinicopathologic significance of FERMT1 and AHCY protein expression in colon cancer. The clinicopathologic significance of FERMT1 and AHCY is summarized in Table 2 . Results of the OS analyses are presented in Fig. 2 The results of the DFS analyses are presented in Fig. 3 and Table 3 . Patients with negative/weak and moderate/strong tumor FERMT1 protein expression had 5-year DFS rates of 69.8% and 54.7% respectively. Kaplan-Meier survival curves showed that patients with moderate/strong tumor FERMT1 protein expression had significantly worse DFS than patients with negative/weak tumor FERMT1 protein expression (P = 0.013).
Similar to the Cox models for OS, T stage, AJCC stage, differentiation, and FERMT1
expression showed independent effects on the risk of disease and were included into the final multivariate Cox proportional hazard model. As seen from the 
Discussion
In the present study, LCM-assisted tissue specimen preparation was combined with In that report, FERMT1 was overexpressed in 70% of the colon carcinomas and 60% of the lung carcinomas tested. In the present study, 66.7% of colon carcinomas showed an increase in FERMT1 expression by 3-to 28-fold, with a mean fold increase of 7.9-fold.
Transforming growth factor-β1 (TGF-β1) contributes to tumor invasion and cancer progression by increasing the motility of tumor cells (40) (41) (42) . Interestingly, FERMT1 is regulated by TGF-β1, and a TGF-β1-induced increase in FERMT1 expression results in increased cell spreading correlated with epithelial to mesenchymal cell transition, an important step in carcinogenesis (43) . It has also been reported that FERMT1 protein is predictive of breast cancer lung metastasis (44) . In the present study, the majority of uninvolved colon tissues and colon adenoma tissues were negative for FERMT1 expression, whereas moderate or strong FERMT1 protein expression was detected in the majority of 
additional experimentation with techniques such as RNA interference in model systems, existing data suggest a strong biologic basis for the association reported herein.
AHCY catalyzes the reversible hydrolysis of S-adenosylhomocysteine to adenosine and L-homocysteine. Thus, it regulates the intracellular S-adenosylhomocysteine concentration, which is thought to be important for transmethylation reactions (GeneCards v.3. http://www.genecards.org/cgi-bin/carddisp.pl?gene=AHCY&search=AHCY ).
Upregulation of AHCY gene expression in colorectal carcinoma compared to uninvolved colon mucosa has been reported in three independent studies of transcript profile analysis with cDNA microarrays (33) (34) (35) (36) . However, validation of differential AHCY protein expression in colon cancer has not been reported. In the present study, we report the first confirmation of elevated AHCY mRNA and protein expression in colon cancer compared to uninvolved colon tissue. Mechanistic studies of AHCY contributions to colon cancer development remain a topic for future investigations.
Comparison of research results obtained with microarrays and SAGE is very complicated owing to the challenges associated with selecting differentially expressed genes from microarray and SAGE data. Fold change and P values are two commonly used criteria for selecting differentially expressed genes. Use of these two ranking criteria often produces different lists of differentially expressed genes (45, 46) . In the present study, 9.4% (404/4300) of the differentially expressed transcripts identified in the microarray data and 47.6% It has been reported that antibody concentration can affect the apparent relation between biomarker expression and outcome (47) . A potential limitation of the present study is that although we performed antibody titration for each antibody used for immunohistochemistry at the beginning of the study, and a single FERMT1 protein band was obtained by Western blot at an antibody dilution of 1:1000 (the same dilution as that used for immunohistochemistry), the fact that we used a single antibody dilution for immunohistochemistry may have led to results that may have differed from those had we used multiple dilutions. Further studies will clarify this issue.
In conclusion, we present the first report using LCM-LongSAGE for quantitative 
